Intranasal delivery of Salmonella OMVs decorated with Chlamydia trachomatis antigens induces specific local and systemic immune responses

Dung T. Huynh,Emanuele Nolfi,Lobna Medfai,Peter van Ulsen,Wouter S. P. Jong,Alice J. A. M. Sijts,Joen Luirink

DOI: https://doi.org/10.1080/21645515.2024.2330768

2024-03-24

Human Vaccines & Immunotherapeutics

Abstract:Chlamydia trachomatis is an obligate intracellular pathogen responsible for the most prevalent bacterial sexually transmitted disease globally. The high prevalence of chlamydial infections underscores the urgent need for licensed and effective vaccines to prevent transmission in populations. Bacterial outer membrane vesicles (OMVs) have emerged as promising mucosal vaccine carriers due to their inherent adjuvant properties and the ability to display heterologous antigens. In this proof-of-concept study, we evaluated the immunogenicity of Salmonella OMVs decorated with C. trachomatis MOMP-derived CTH522 or HtrA antigens in mice. Following a prime-boost intranasal vaccination approach, two OMV-based C. trachomatis vaccines elicited significant humoral responses specific to the antigens in both systemic and vaginal compartments. Furthermore, we demonstrated strong antigen-specific IFN-γ and IL17a responses in splenocytes and cervical lymph node cells of vaccinated mice, indicating CD4 + Th1 and Th17 biased immune responses. Notably, the OMV-CTH522 vaccine also induced the production of spleen-derived CD8 + T cells expressing IFN-γ. In conclusion, these results highlight the potential of OMV-based C. trachomatis vaccines for successful use in future challenge studies and demonstrate the suitability of our modular OMV platform for intranasal vaccine applications.

immunology,biotechnology & applied microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop an effective vaccine against Chlamydia trachomatis. Chlamydia trachomatis is a pathogen that causes the most common bacterial sexually transmitted disease worldwide. It has a high infection rate and is often asymptomatic, making it difficult for intervention strategies to effectively control its spread in the population. Currently, antibiotic treatment is mainly relied on. However, due to its partial intracellular lifestyle and its ability to enter a persistent state under stress conditions, there is an urgent need to develop a broadly protective vaccine.

The paper proposes an intranasal delivery system based on bacterial outer membrane vesicles (OMVs) to display the antigens of Chlamydia trachomatis in order to induce specific local and systemic immune responses. Specifically, the researchers used OMVs from Salmonella and decorated their surfaces with CTH522 derived from the major outer membrane protein (MOMP) of Chlamydia trachomatis or the inactivated HtrA antigen, and carried out immunization experiments in mice via the intranasal route.

The main objectives of the study were to evaluate the effectiveness of these OMV - based vaccines in inducing specific immune responses, including:

1. **Humoral immune response**: To detect whether the vaccine can induce antigen - specific antibodies at the systemic and vaginal sites.
2. **Cellular immune response**: To assess whether the vaccine can trigger antigen - specific IFN - γ and IL - 17a responses in splenocytes and cervical lymph node cells, indicating CD4+ Th1 and Th17 - biased immune responses.
3. **Cytotoxic T - cell response**: To pay special attention to whether the OMV - CTH522 vaccine can induce IFN - γ production by spleen - derived CD8+ T cells.

Through these experiments, the researchers hope to verify the potential of OMV - based vaccines as candidate vaccines in future challenge studies, either alone or in combination with other immunization strategies.